1. Generics Bulletin

Celltrion’s Subcutaneous Infliximab Shows Promise

 
• By Dave Wallace

Data revealed by Korea’s Celltrion demonstrates that the firm’s subcutaneous infliximab is comparable to the intravenous formulation, with a study showing that auto-injection is a viable administrative method.

Injection
Celltrion Has Revealed Data To Support Its Subcutaneous Infliximab • Source: Shutterstock

Celltrion’s subcutaneous (SC) formulation of its CT-P13 biosimilar infliximab is “comparable in terms of efficacy and safety” with the intravenous (IV) formulation, according to data from a year-long study that has just been revealed by the Korean company.

“The SC formulation of CT-P13 was comparable in terms of efficacy and safety with the IV formulation for the treatment of Crohn’s disease up until week 54,” Celltrion said, “indicating that

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products